Chelsea Therapeutics International Ltd.(NASDAQ : CHTP)
(
)
Volume
Open
Day's Low
Day's High
52 Wk Low
52 Wk High
Bid
Ask
EPS
PE Ratio
Shares
Market Cap
Dividend
Ex-Div Date
Yield
Yes, 3x ETFs are Awesome!
Like TNA, UGAZ, UWTI, NUGT? We do too...Join Up!
...
Health Technology » Biotechnology
| symbol | company | %chng | last | %short | avg$volume | |
|---|---|---|---|---|---|---|
| MRNA | Moderna, Inc. | -6.73% | 146.81 | 0.0% | $1534.10m | |
| OCGN | Ocugen, Inc. | -4.19% | 9.60 | 0.0% | $1069.86m | |
| NVAX | Novavax, Inc. | -14.27% | 205.99 | 92.9% | $909.19m | |
| AMGN | Amgen, Inc. | -0.60% | 225.69 | 1.3% | $548.32m | |
| VRTX | Vertex Pharmaceuticals, Inc. | 0.80% | 212.06 | 1.9% | $521.91m | |
| REGN | Regeneron Pharmaceuticals, Inc. | -1.77% | 454.86 | 2.7% | $509.91m | |
| ILMN | Illumina, Inc. | -1.23% | 441.01 | 3.5% | $504.66m | |
| GILD | Gilead Sciences, Inc. | 0.88% | 63.01 | 1.0% | $479.35m | |
| ALXN | Alexion Pharmaceuticals, Inc. | -1.05% | 150.37 | 2.0% | $354.39m | |
| BNGO | Bionano Genomics, Inc. | -3.66% | 9.48 | 0.0% | $340.06m | |
| BIIB | Biogen, Inc. | -1.24% | 269.85 | 1.7% | $329.36m | |
| CRSP | CRISPR Therapeutics AG | -0.37% | 129.77 | 0.6% | $302.39m | |
| EXAS | EXACT Sciences Corp. | -2.72% | 136.39 | 18.4% | $253.67m | |
| SGEN | Seagen Inc. | 0.76% | 153.71 | 5.8% | $214.53m | |
| VXRT | Vaxart, Inc. | -5.43% | 7.14 | 0.0% | $189.51m |
Company Profile
Chelsea Therapeutics International, Ltd. is a development stage pharmaceutical company that focuses on acquiring, developing and commercializing products for the treatment of a variety of human diseases. The Company is developing a therapeutic agent for the treatment of symptomatic neurogenic orthostatic hypotension (NOH), and related conditions and diseases along with its development of prescription products for multiple autoimmune disorders, including rheumatoid arthritis, psoriasis, inflammatory bowel disease and cancer. As of December 31, 2009, it was focused on its drug development resources on two clinical stage development projects: droxidopa for symptomatic NOH and other potential indications, and its portfolio of non-metabolized antifolate compounds for the treatment of rheumatoid arthritis.